2149: Respiratory Virus Post-Infusion Data

In an effort to collect data on the impact of the COVID-19 (SARS-CoV-2) pandemic on our transplant and cellular therapy recipients, CIBMTR released the Respiratory Virus Post-Infusion Data (2149) Form. This form captures information regarding the diagnosis, treatment, and response to treatment of COVID-19 (SARS-CoV-2) diagnosed after a transplant or cellular therapy infusion.

*As of August 25, 2023, this form will no longer come due if COVID-19 (SARS-CoV-2) is reported as an infectious organism or cause of death (primary or contributing) on the Post-HCT Follow-Up (2100), Post-TED (2450), Recipient Death (2900), or Cellular Therapy Essential Data Follow-Up (4100) forms.

The Respiratory Virus Post-Infusion Data (2149) Form will no longer have the option to be created on-demand (on-demand is when a form can be generated at any time).

This form will be completed at two timepoints, “Initial” and “Follow-up”:

• Initial Form Submission: reported data should be between 7 days prior to and up to 14 days after the date of diagnosis.
• Follow-Up Form Submission: reported data should be between the date of evaluation (from the initial form submission) to the date of the infection resolution (or day of death).
  

Links to Form Sections:
Q1-10: Infection Diagnosis
Q11-24: Hematologic Findings at Diagnosis of Infection
Q25-40: Therapy

Manual Updates:
Sections of the Forms Instruction Manual are frequently updated. The most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

If you need to reference the historical Manual Change History for this form, reference the retired manual section on the Retired Forms Manuals webpage.

Date	Manual Section	Add/Remove/Modify	Description
8/25/2023	2149: Respiratory Virus Post-Infusion Data	Modify	Updated the Respiratory Virus Post-Infusion Data (2149) form instructions to reflect that this form will no longer come due automatically or be available on-demand for recipients on the CRF or cellular therapy tracks when there is a diagnosis of COVID-19 post-infusion.
7/8/2020	2149: Respiratory Virus Post-Infusion Data	Add	Provided information on CRISPR testing for questions 2 – 3: Nasal swab / wash: a sample is collected from the nose using a swab or a small amount of saline solution. The sample is tested via polymerase chain reaction techniques that quantify the amount of viral RNA present or using novel CRISPR testing from respiratory swab RNA extracts. If the amount of viral RNA is above the upper limit of normal (found on the laboratory report), the result will be considered positive for the virus being tested. If the testing report does not clearly indicate whether the result was positive, negative, or equivocal, contact your center’s lab for clarification.
5/10/2020	2149: Respiratory Virus Post-Infusion Data	Add	Version 1 of the 2149: Respiratory Virus Post-Infusion Data section of the Forms Instruction Manual released. Version 1 corresponds to revision 1 of the Form 2149.

Copyright © 2004-2024 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.